Milestone Pharmaceuticals (MIST) Share-based Compensation (2018 - 2026)

Milestone Pharmaceuticals (MIST) has reported Share-based Compensation for 9 consecutive years, with $13.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Share-based Compensation rose 23.38% year-over-year to $13.9 million; the trailing twelve-month figure through Jun 2026 stood at $13.9 million (up 23.38% YoY), and the FY2025 full-year result was $10.6 million, up 8.87% from the prior year.
• Share-based Compensation rose to $13.9 million in Q2 2026 per MIST's latest filing, from $13.1 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $20.6 million in Q1 2022 and bottomed at $1.5 million in Q4 2024.
• Historically, Share-based Compensation has averaged $11.1 million across 5 years, with a median of $11.2 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation tumbled 51.41% in 2024, then jumped 140.98% in 2025.
• Over 5 years, Share-based Compensation stood at $2.1 million in 2022, then declined by 12.41% to $1.9 million in 2023, then slipped by 21.47% to $1.5 million in 2024, then surged by 140.98% to $3.6 million in 2025, then surged by 291.89% to $13.9 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $13.9 million, $13.1 million, and $3.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.